Science
September 3, 2026
Mario Heles, Lilach Pasvolsky, Hinduja Sathishkumar et al.
Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling, often irreversible toxicity that affects millions of patients, limits life-saving cancer therapy, and lacks proven treatment. In this work, we show that as little as two doses of psilocybin before chemotherapy durably prevented the onset of CIPN across platinum- and taxane-based models, including repeated chemotherapy cycles,...
Zenodo (CERN European Organization for Nuclear Research)
September 2, 2026
Andrea Vittorini
preprint
This hypothesis and perspective article proposes that uninterrupted daily low-dose psilocybin may constitute a pharmacologically distinct receptor-adaptation paradigm. Repeated 5-HT2A agonist pulses could progressively produce functional desensitization, internalization, and/or down-regulation; the fading of acute subjective effects may therefore mark the development of an adaptive state rather...
Biological Psychiatry Global Open Science
September 1, 2026
Elizabeth A Virakorn, Kathryn Baker, Nicholas A. Everett et al.
Background Recent work suggests that psilocybin, a hallucinogenic 5-HT 2A R agonist with rapid and long-lasting anti-depressant actions, facilitates fear extinction retention in adult rodents. However, psilocybin’s effects on adolescent fear extinction are unknown. Further, chronic stress in adolescence predisposes individuals to developing psychopathologies such as anxiety and fear-related...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Kusudo, K Yonezawa, Sota Tomiyama et al.
Abstract Background Psilocybin, a prodrug metabolized to psilocin, a serotonin 2A receptor agonist, has reemerged as a promising therapeutic option for treatment-resistant depression (TRD). Clinical trials conducted mainly in North America and Europe have demonstrated that psilocybin administered with psychological support can produce rapid and sustained antidepressant effects with favorable...
The International Journal of Neuropsychopharmacology
September 1, 2026
Christopher Sheridan, Guillaume Thuery, K Brennan et al.
Abstract Background Serotonergic psychedelics have recently re-emerged as promising therapeutic agents in psychiatry, showing positive outcomes in clinical trials for treatment-resistant depression, major depression, and PTSD. However, their effects on the immune system are poorly characterized. It remains unclear whether these compounds exert immunomodulatory effects that contribute to their...
The International Journal of Neuropsychopharmacology
September 1, 2026
Jessica Mingardi, Stefano Spinosa, Noemi Nicosia et al.
Abstract Background Stress is a recognized risk factor for developmental and adult psychiatric disorders. Indeed, stressful events, particularly during the first phases of life, such as trauma, neglect or abuse, have been associated with increased psychiatric risk over the course of a lifetime, although with some sex-differences. Indeed, the biological sex shapes the stress response impacting...
The International Journal of Neuropsychopharmacology
September 1, 2026
K Yonezawa, K Kusudo, Sota Tomiyama et al.
Abstract Background Despite recent advances in the treatment of major depression, approximately 30% of patients show insufficient improvement with conventional antidepressants, a condition commonly referred to as treatment-resistant depression (TRD). Psilocybin is a classic psychedelic compound that has received renewed attention as a promising therapeutic candidate for TRD. Clinical trials...
The International Journal of Neuropsychopharmacology
September 1, 2026
Ella Nield, Martha López-canul, Antonio Inserra et al.
Abstract Background Pain conditions are major health problems resulting in physical, psychological and social impairment (1), and health care costs (2,3). Within the last decade, research has demonstrated that 5-HT2A agonists including psilocybin and LSD elicit spiritual experiences (4) and functional connectivity changes between diverse brain areas (5). Therefore, it is pertinent to...
Neuroscience Research
September 1, 2026
Mersedeh Shamsedin
ABSTRACT Background Fronto-hippocampal desynchronization is linked to cognitive decline in Alzheimer's-like pathology, but whether psilocybin can restore this dysfunction is unknown. Methods Male rats received intracerebroventricular streptozotocin (ICV-STZ) to induce neurotoxicity, followed by a single dose of psilocybin (2.5 mg/kg, the maximum tolerated dose). Spatial memory, recognition...
Human Psychopharmacology: Clinical and Experimental
September 1, 2026
José Norberto Vásquez-Bonilla
OBJECTIVE: This review critically examines psilocybin, with particular emphasis on its pharmacokinetics and pharmacodynamics, including its serotonergic, neuroplastic, and anti-inflammatory mechanisms. It integrates historical context, preclinical and clinical evidence, and evaluates emerging therapeutic potential, safety, microdosing practices, and pharmacological interactions. METHODS: A...